Skip to main content
OpenTrials
Completed

NCT Number: NCT03639649

STHLM3 - Prostate Cancer Diagnostic Trial

STHLM3 is a paired diagnostic trial aiming to assess whether a panel of biomarkers for prostate cancer can substantially reduce the proportion of men referred to biopsy whilst maintaining sensitivity for aggressive prostate cancer

Completed

Looking for future studies?

Notify Me

Key information

Age range

50 year–69 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

Karolinska Institutet

Stockholm, 17177, Sweden

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 50-69
  • Residential address in Stockholm County

Exclusion criteria

  • Previous Prostate Cancer Diagnosis
  • Not able to comprehend inform consent material

Treatment and study plan

STHLM3

Diagnostic Test

Primary outcomes

  1. Number of biopsies

    Time frame: Recorded directly after biopsy

Secondary outcomes

  1. Number of Gleason Score ≥ 7

    Time frame: Recorded directly after biopsy

  2. Number of Gleason Score 6

    Time frame: Recorded directly after biopsy

  3. Number of benign

    Time frame: Recorded directly after biopsy

Sponsors and collaborators

Lead sponsor

Karolinska Institutet

Other

Collaborators

  • Region Stockholm

Registry information

Acronym: STHLM3

Important dates

Study start
2013
Primary completion
2015
Study completion
2015
First posted
Aug 21, 2018
Registry last updated
Aug 21, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.